Blockbuster antibody therapies have catapulted immune‐based approaches to treat cancer
into the consciousness of mainstay clinical research. On the back of this, other emerging …

The engineered expression of chimeric antigen receptors (CARs) on the surface of T cells
enables the redirection of T-cell specificity. Early clinical trials using CAR T cells for the …

Cell‐based therapies using chimeric antigen receptor T cells (CAR T) have had dramatic
efficacy in the clinic and can even mediate curative responses in patients with hematologic …

Chimeric antigen receptor (CAR)-engineered T cells represent a breakthrough in
personalized medicine. In this strategy, a patient's own T lymphocytes are genetically …

The development of novel targeted therapies with acceptable safety profiles is critical to
successful cancer outcomes with better survival rates. Immunotherapy offers promising …

Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved unprecedented
efficacy in the treatment of chemotherapy-resistant or refractory B-cell malignancies …

Chimeric antigen receptor‐(CAR‐) T cell therapy is one of the most recent innovative
immunotherapies and is rapidly evolving. Like other technologies, CAR‐T cell therapy has …

Chimeric antigen receptor (CAR) T cell therapies have evolved from a research tool to a
concept-shifting therapy with impressive responses in B cell malignancies. This Review …

Adoptive immunotherapy with chimeric antigen receptor-modified (CAR)-T cells is a rapidly
growing therapeutic approach to treating patients with refractory cancer, with over 100 …

In the past 50 years, disease burden has steadily shifted from infectious disease to cancer.
Standard chemotherapy has long been the mainstay of cancer medical management, and …